Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 8/20 | 0.40 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.35 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 5/20 | 0.34 |
| ▸ | CTSS | P25774 | 5/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | BCR | P11274 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4041605 | 0.89 | MAPK14 (0.40) | ALDH1A1LMNAPKMCTSKCTSL | |
| SCHEMBL4047319 | 0.88 | CTSK (0.42) | ALDH1A1HTTSMN1; SMN2LMNAGLA | |
| SCHEMBL4043068 | 0.87 | HDAC1 (0.36) | LMNAPKMCTSKCTSLCTSS | |
| SCHEMBL4046192 | 0.86 | LMNA (0.40) | ALDH1A1HTTSMN1; SMN2LMNACTSK | |
| SCHEMBL4044060 | 0.86 | PLA2G1B (0.40) | ALDH1A1HTTSMN1; SMN2LMNAGLA | |
| SCHEMBL4047880 | 0.82 | CTSK (0.48) | ALDH1A1LMNACTSKPLA2G1BATG4B | |
| SCHEMBL4038260 | 0.81 | CTSK (0.38) | ALDH1A1HTTLMNACTSKKMT2A | |
| SCHEMBL4045826 | 0.80 | TSHR (0.35) | ALDH1A1CTSKCTSLCTSSTSHR | |
| SCHEMBL4039586 | 0.80 | CTSK (0.65) | ALDH1A1HTTSMN1; SMN2LMNAGLA | |
| SCHEMBL4043534 | 0.80 | CTSK (0.39) | ALDH1A1HTTLMNACTSKNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | claimed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | claimed |
| US-7556860-B2 | Laminate and method of forming the same, insulating film, and semiconductor device | JSR CORPORATION (JP) | 2009-07-07 | — | — | US | disclosed |
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| EP-2013184-A1 | SULFONAMIDE COMPOUNDS USEFUL AS EDG RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2009-01-14 | — | — | EP | disclosed |
| US-20080246153-A1 | ORGANIC SILICA-BASED FILM, METHOD OF FORMING THE SAME, COMPOSITION FOR FORMING INSULATING FILM FOR SEMICONDUCTOR DEVICE, INTERCONNECT STRUCTURE, AND SEMICONDUCTOR DEVICE | JSR CORPORATION (JP) | 2008-10-09 | — | — | US | disclosed |
| WO-2007129019-A1 | SULFONAMIDE COMPOUNDS USEFUL AS EDG RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | disclosed |
| US-7291567-B2 | Silica-based film, method of forming the same, composition for forming insulating film for semiconductor device, interconnect structure, and semiconductor device | JSR CORPORATION (JP) | 2007-11-06 | — | — | US | disclosed |
| US-20060024980-A1 | Silica-based film, method of forming the same, composition for forming insulating film for semiconductor device, interconnect structure, and semiconductor device | JSR CORPORATION (JP) | 2006-02-02 | — | — | US | disclosed |
| EP-1546150-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | Amura Therapeutics Limited (GB) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004007501-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100431-A1 | Biologically active compounds | SOST, CTSK, CTSS | ALDH1A1 4151/4885HTT 2905/4885SMN1; SMN2 3546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.